{
    "pmcid": "9356539",
    "qa_pairs": {
        "What is a key implication for nanobody design highlighted by the study?": [
            "Targeting conserved epitopes on the spike protein to ensure broad-spectrum activity.",
            "Focusing on the development of nanobodies that bind only the RBD.",
            "Designing nanobodies that are specific to the wild-type spike protein.",
            "Creating nanobodies that can only neutralize the Alpha variant."
        ],
        "What is the primary advantage of the Rapid In-Vitro Inhibition Assay (RIVIA) over traditional virus neutralization tests and pseudovirus neutralization assays?": [
            "RIVIA is faster and more accessible, requiring less specialized facilities.",
            "RIVIA provides more accurate results than traditional tests.",
            "RIVIA can detect a wider range of viral variants than other assays.",
            "RIVIA is less expensive to perform than other neutralization assays."
        ],
        "What is the significance of the slope of inhibition curves in the RIVIA according to the study?": [
            "It suggests potential for optimizing nanobody design based on binding kinetics.",
            "It indicates the overall efficacy of the nanobody against the virus.",
            "It correlates with the ability of the nanobody to cross-react with different variants.",
            "It reflects the stability of the nanobody under physiological conditions."
        ],
        "Which form of the SARS-CoV-2 spike protein was identified as the best mimic for physiological conditions in the RIVIA?": [
            "S-ECD homotrimer",
            "RBD",
            "S1 subunit",
            "S-ECD monomer"
        ],
        "Which nanobody was found to lose its neutralizing ability against the Beta variant due to immune-evasive mutations?": [
            "Nb21",
            "Nb34",
            "Nb93",
            "Nb95"
        ]
    }
}